ArticleHuman vaccines & immunotherapeutics2016
No evidence that HPV vaccination leads to sexual risk compensation.
Article in Human vaccines & immunotherapeutics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 12 citations in OpenAlex.
- Behavioral intention to perform risk compensation behaviors after receiving HPV vaccination among men who have sex with men in China.Human vaccines & immunotherapeutics · 2019Trial
- Effect of human papillomavirus (HPV) vaccine on HPV type replacement and sexual behaviors in the post-vaccine era: A cross-sectional study.Human vaccines & immunotherapeutics · 2025Article
- Development of an overarching framework for anticipating and assessing adverse and other unintended consequences of public health interventions (CONSEQUENT): a best-fit framework synthesis.BMJ public health · 2024Article
- Article
- Association between health behaviours and the COVID-19 vaccination: risk compensation among healthcare workers in Taizhou, China.Human vaccines & immunotherapeutics · 2022Article
- Give PrEP a chance: moving on from the "risk compensation" concept.Journal of the International AIDS Society · 2019Article
- The nonavalent vaccine: a review of high-risk HPVs and a plea to the CDC.American journal of stem cells · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Uptake of the HPV vaccine has been lower than the uptake of most other childhood vaccines offered in public programs. Since the HPV vaccine protects against a sexually transmitted virus, one barrier to uptake specific to the HPV vaccine may be the concern that vaccination may encourage risky sexual behaviour. Unanimous findings from recent studies show that HPV vaccination does not lead to sexual risk compensation, which is an important message to parents, clinicians and other decision-makers regarding HPV vaccination. Some issues remain to be investigated, like HPV vaccination and sexual risk compensation among boys.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.